PHILADELPHIA, May 23, 2025 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on the Trials in Progress poster presentation at the upcoming 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, being held from May 30 – June 3, 2025 in Chicago, IL. The trial Principal Investigator, Janos L. Tanyi, MD, PhD, of the Perelman School of Medicine at the University of Pennsylvania, will present an overview

SHANGHAI, May 23, 2025 /PRNewswire/ -- Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first administration of its proprietary Parkinson's disease cell drug UX-DA001 in China in March 2025. The Phase I clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of UX-DA001 in patients with Parkinson's disease. On March 1, 2025, Dr. Li Dianyou, Director of the Functional Neurosurg

Initial safety & efficacy in patients with Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC) with Driver Genomic Alterations (GA) outside of Classic EGFR Mutations will be presented from clinical studies evaluating iza-bren, an EGFRxHER3 bispecific topoisomerase inhibitor- based antibody-drug conjugate (ADC) REDMOND, Wash., May 23, 2025 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that two abstracts on izalontamab bren

Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responses New analyses confirm that pelareorep primes the TME to allow circulating tumor-infiltrating lymphocytes (TILs) in the blood to attack tumors Pre-existing TIL clones in plasma may correlate positively with tumor shrinkage in pancreatic cancer SAN DIEGO and CALGARY, AB, May 23, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company

CHENGDU, China, May 23, 2025 /PRNewswire/ -- The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, the "Company") will present results from six clinical studies, including data on its TROP2 ADC sac-TMT, anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586 (A400/EP0031) during the meeting. The study abstracts were published on the ASCO website o

First deployment of robotic bronchoscopy in Korea South Korea's National Cancer Center is set to introduce robotic-assisted endoscopic imaging for lung cancer diagnosis. This is a Korea-first deployment of the robotic bronchoscopy platform by United States-based Intuitive Surgical, according to a media release. The high-precision technology is expected to address the present limitations in diagnosing lung cancer through tissue examination in the country. The robotic platform is also set to be de

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically meaningful results from the phase-III PROTECT trial 4 ST. GALLEN, Switzerland, May 23, 2025 /PRNewswire/ -- CSL Vifor is pleased to announce that the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that sparsentan can be used in the NHS in England

PHILADELPHIA, PA, USA I May 22, 2025 I GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab)as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilicphenotype. FDA’s approval was based on data from the positive MATINEE and METREX phase III trials. Across these trials, mepolizumab showed a clinically meaningful and statistically significant reduction in the annualized rate of moder

–  63% response rate observed among 43 evaluable patients –  79% overall survival rate at 12-months; 9 months median progression-free survival UTRECHT, The Netherlands and CAMBRIDGE, MA, USA I May 22, 2025 I Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ® , Triclonics ® and ADClonics ® ), today announced interim clinical data as of a February 27, 2025 data cutoff

Malaysia's communications regulator has recently piloted medicine drone delivery in Sabah. The Malaysian Communications and Multimedia Commission (MCMC) partnered with the Ministry of Health, the Malaysian Research Accelerator for Technology and Innovation, and local drone technology providers to test the viability of drone-based delivery of medicines in rural and remote areas. According to a report by Malaysia's national news agency, Bernama, the first phase of the pilot involves two community